Comparison of graft-versus-host disease-free, relapse-free survival of transplantation using matched sibling donor, matched unrelated donor or unrelated cord blood after myeloablative conditioning for adult patients with hematological malignancies

Leukemia & Lymphoma
T KonumaSatoshi Takahashi

Abstract

The novel composite endpoint of graft-versus-host disease/relapse-free survival (GRFS) was proposed to evaluate ideal healthy recovery without ongoing morbidity in patients undergoing allogeneic hematopoietic cell transplantation (HCT). We herein analyzed long-term GRFS based on the data of 256 patients with hematological malignancies who underwent allogeneic HCT after myeloablative conditioning. The probabilities of GRFS in the entire cohort were 60.1% at 1 year, and 48.6% at 5 years. Compared with unrelated cord blood, the probability of treatment failure as defined by GRFS at 5 years was similar with matched sibling donor (hazard ratio [HR]: 1.33; p = 0.28), but was significantly higher with matched unrelated donor (HR: 1.96; p = 0.01) in multivariate analysis. Unrelated cord blood achieved the highest proportion of patients who had not experienced any GRFS events at 5 years. These data suggest that long-term GRFS after HCT was similar in matched sibling donor recipients to unrelated cord blood recipients.

References

Sep 21, 2000·British Journal of Haematology·S ChiodiA Bacigalupo
Nov 27, 2004·The New England Journal of Medicine·Mary J LaughlinMary M Horowitz
Nov 27, 2004·The New England Journal of Medicine·Vanderson RochaUNKNOWN Eurocord-Netcord Registry
Jul 5, 2006·Bone Marrow Transplantation·S J LeeJ H Antin
Jun 19, 2010·The Lancet Oncology·Mary EapenUNKNOWN National Cord Blood Program of the New York Blood Center
Nov 26, 2010·The New England Journal of Medicine·Ted A GooleyGeorge B McDonald
Mar 29, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Joseph PidalaClaudio Anasetti
Apr 16, 2013·Bone Marrow Transplantation·L F NewellC Delaney
Jun 25, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Régis Peffault de LatourDaniel Weisdorf
Oct 1, 2013·Bone Marrow Transplantation·J KandaM Murata
Apr 15, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Takaaki KonumaSatoshi Takahashi
Oct 11, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Julie A RossMichael R Verneris

❮ Previous
Next ❯

Citations

Feb 26, 2016·American Journal of Hematology·Takaaki KonumaUNKNOWN Donor/Source Working Group of the Japan Society for Hematopoietic Cell Transplantation
Apr 6, 2017·Expert Opinion on Biological Therapy·Sofia BerglundMichael Uhlin
Jan 5, 2021·Japanese Journal of Clinical Oncology·Motohito OkabeArinobu Tojo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.